Orange Book product · Brand (NDA)
BYDUREON BCISE
EXENATIDE SYNTHETIC
At a glance
Oct 20, 2017
Approved
Brand (NDA)
Application
Not listed
TE code
47
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 20, 2017
8 yr 9 mo ago
Patent 6515117 expires
Listed drug substance patent expiration.
Oct 04, 2025
9 mo ago
Patent 6515117*PED expires
Listed listed patent expiration.
Apr 04, 2026
3 mo ago
Today
Patent 8329648 expires
Listed method-of-use patent (U-2590) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-2593) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-2594) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-2596) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-2595) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-2588) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-2589) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-3189) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-3188) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648 expires
Listed method-of-use patent (U-3190) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-2590) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-2593) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-2597) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-2589) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-3188) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-3189) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-2588) expiration.
Aug 18, 2026
in 2 mo
Patent 8906851 expires
Listed method-of-use patent (U-3190) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2593) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2589) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2594) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2596) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2597) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2595) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2590) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-2588) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-3188) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-3190) expiration.
Aug 18, 2026
in 2 mo
Patent 9884092 expires
Listed method-of-use patent (U-3189) expiration.
Aug 18, 2026
in 2 mo
Patent 8329648*PED expires
Listed listed patent expiration.
Feb 18, 2027
in 8 mo
Patent 8906851*PED expires
Listed listed patent expiration.
Feb 18, 2027
in 8 mo
Patent 9884092*PED expires
Listed listed patent expiration.
Feb 18, 2027
in 8 mo
Patent 8501698 expires
Listed method-of-use patent (U-2588) expiration.
Jun 20, 2027
in 1 yr
Patent 8501698*PED expires
Listed listed patent expiration.
Dec 20, 2027
in 1 yr 6 mo
Patent 8361972 expires
Listed method-of-use patent (U-2588) expiration.
Mar 21, 2028
in 1 yr 9 mo
Patent 8361972*PED expires
Listed listed patent expiration.
Sep 21, 2028
in 2 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033 expires
Listed drug product patent expiration.
Oct 04, 2030
in 4 yr 4 mo
Patent 8895033*PED expires
Listed listed patent expiration.
Apr 04, 2031
in 4 yr 10 mo
Pharmaceutical detail
Active ingredient
EXENATIDE SYNTHETIC
Strength
2MG/0.85ML (2MG/0.85ML)
Dosage form
SUSPENSION, EXTENDED RELEASE
Route
SUBCUTANEOUS
TE code
Not listed
Application
NDA 209210
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (47)
| Patent | Expires | In | Type |
|---|---|---|---|
| 6515117 | Oct 04, 2025 | 9 mo ago | SubstanceProductU-2588 |
| 6515117*PED | Apr 04, 2026 | 3 mo ago | |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2590 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2593 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2594 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2596 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2595 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2588 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-2589 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-3189 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-3188 |
| 8329648 | Aug 18, 2026 | in 2 mo | U-3190 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-2590 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-2593 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-2597 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-2589 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-3188 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-3189 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-2588 |
| 8906851 | Aug 18, 2026 | in 2 mo | U-3190 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2593 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2589 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2594 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2596 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2597 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2595 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2590 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-2588 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-3188 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-3190 |
| 9884092 | Aug 18, 2026 | in 2 mo | U-3189 |
| 8329648*PED | Feb 18, 2027 | in 8 mo | |
| 8906851*PED | Feb 18, 2027 | in 8 mo | |
| 9884092*PED | Feb 18, 2027 | in 8 mo | |
| 8501698 | Jun 20, 2027 | in 1 yr | U-2588 |
| 8501698*PED | Dec 20, 2027 | in 1 yr 6 mo | |
| 8361972 | Mar 21, 2028 | in 1 yr 9 mo | U-2588 |
| 8361972*PED | Sep 21, 2028 | in 2 yr 4 mo | |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-2597 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-2590 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-2601 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-2589 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-2602 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-3190 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-3188 |
| 8895033 | Oct 04, 2030 | in 4 yr 4 mo | ProductU-3189 |
| 8895033*PED | Apr 04, 2031 | in 4 yr 10 mo |

